The antiepileptic drugs market size has grown strongly in recent years. It will grow from $17.01 billion in 2024 to $18.0 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be linked to the increasing prevalence of epilepsy, heightened awareness of neurological disorders, progress in drug development, government support and funding for epilepsy research, and the expansion of healthcare infrastructure in emerging markets.
The antiepileptic drugs market size is expected to see strong growth in the next few years. It will grow to $22.27 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The anticipated growth in the forecast period is driven by a rising number of patients with drug-resistant epilepsy, advancements in personalized medicine for epilepsy treatment, increased adoption of biologics and gene therapies, growing investments in epilepsy research and development, and improvements in diagnostics that enhance the identification of epilepsy cases. Key trends expected during this period include the advancement of personalized treatment approaches, progress in combination therapies for drug-resistant epilepsy, emerging therapies targeting specific genetic mutations, a stronger focus on developing safer and more effective antiepileptic drugs (AEDs), and expanded use of cannabidiol-based therapies for seizure control.
The rising prevalence of epilepsy is expected to drive the growth of the antiepileptic drugs market in the coming years. Epilepsy is a neurological disorder marked by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. An increase in head injuries from accidents contributes to a higher risk of developing epilepsy due to brain trauma and neural damage. Antiepileptic drugs (AEDs) work by stabilizing brain activity through modulation of neurotransmitters and ion channels to prevent excessive neuron firing. These drugs reduce both the frequency and severity of seizures, thereby improving the quality of life for people with epilepsy. For example, in February 2022, Epilepsy Action, a UK-based charity that supports individuals with epilepsy, reported that approximately 630,000 people in the UK live with epilepsy - about one in every 100 people - with 80 new cases diagnosed daily. Thus, the growing prevalence of epilepsy is contributing to the expansion of the antiepileptic drug market.
Leading companies in the antiepileptic drugs market are focusing on developing advanced formulations, such as intravenous (IV) antiepileptic drugs, to provide more effective treatment options for acute seizures and emergency situations. IV antiepileptic drugs are fast-acting medications administered directly into the bloodstream via injection or infusion, offering rapid seizure control, especially in emergencies or when oral medications are not suitable or effective. For instance, in January 2024, Eisai Co., Ltd., a Japan-based pharmaceutical firm, received manufacturing and marketing approval for Fycompa in Japan. Fycompa is a first-in-class, highly selective, non-competitive AMPA receptor antagonist that decreases neuronal hyper-excitation linked to seizures by targeting glutamate activity at AMPA receptors. The intravenous formulation was developed as an alternative for epilepsy patients who temporarily cannot take oral medication, such as during surgery, to reduce seizure risks associated with interrupted oral dosing. Fycompa is approved in over 75 countries and is used as an adjunctive treatment for partial-onset seizures and primary generalized tonic-clonic seizures in patients aged 4 years and older in Japan.
In August 2024, AbbVie, a U.S.-based biopharmaceutical company, acquired Cerevel Therapeutics for around $8.7 billion. This acquisition is intended to strengthen AbbVie’s neuroscience pipeline and enhance its capacity to develop treatments for neurological and psychiatric disorders. Cerevel Therapeutics is a U.S.-based biotechnology company specializing in the manufacture of antiepileptic drugs.
Major players in the antiepileptic drugs market are Pfizer Inc., Sanofi S.A., Novartis AG, Teva Pharmaceutical Industries Ltd., UCB S.A., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Jazz Pharmaceuticals plc, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Ltd., Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Supernus Pharmaceuticals Inc., SK Biopharmaceuticals Co. Ltd., Immedica Pharma AB, Neurelis Inc.
North America was the largest region in the antiepileptic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in antiepileptic drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the antiepileptic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Antiepileptic drugs (AEDs) are medications used to control or prevent seizures in people with epilepsy and other neurological disorders. They work by altering neurotransmitter levels or ion channel function in the brain. By stabilizing electrical activity in the brain, AEDs help decrease both the frequency and severity of seizures.
The main categories of antiepileptic drugs include first-generation, second-generation, and third-generation AEDs. First-generation AEDs were the earliest seizure treatments and act by stabilizing brain activity, though they often come with more side effects and complex pharmacokinetics. These drugs come in various forms, including dry and liquid formulations, and can be administered through multiple routes such as oral and intravenous. They are distributed through a range of channels, including hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.
The antiepileptic drugs market research report is one of a series of new reports that provides antiepileptic drugs market statistics, including the antiepileptic drugs industry global market size, regional shares, competitors with the antiepileptic drugs market share, detailed antiepileptic drugs market segments, market trends, opportunities, and any further data you may need to thrive in the antiepileptic drugs industry. This antiepileptic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The antiepileptic drugs market consists of sales of sodium channel blockers, calcium channel blockers, glutamate inhibitors, and gamma-aminobutyric acid (GABA) enhancers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The antiepileptic drugs market size is expected to see strong growth in the next few years. It will grow to $22.27 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The anticipated growth in the forecast period is driven by a rising number of patients with drug-resistant epilepsy, advancements in personalized medicine for epilepsy treatment, increased adoption of biologics and gene therapies, growing investments in epilepsy research and development, and improvements in diagnostics that enhance the identification of epilepsy cases. Key trends expected during this period include the advancement of personalized treatment approaches, progress in combination therapies for drug-resistant epilepsy, emerging therapies targeting specific genetic mutations, a stronger focus on developing safer and more effective antiepileptic drugs (AEDs), and expanded use of cannabidiol-based therapies for seizure control.
The rising prevalence of epilepsy is expected to drive the growth of the antiepileptic drugs market in the coming years. Epilepsy is a neurological disorder marked by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. An increase in head injuries from accidents contributes to a higher risk of developing epilepsy due to brain trauma and neural damage. Antiepileptic drugs (AEDs) work by stabilizing brain activity through modulation of neurotransmitters and ion channels to prevent excessive neuron firing. These drugs reduce both the frequency and severity of seizures, thereby improving the quality of life for people with epilepsy. For example, in February 2022, Epilepsy Action, a UK-based charity that supports individuals with epilepsy, reported that approximately 630,000 people in the UK live with epilepsy - about one in every 100 people - with 80 new cases diagnosed daily. Thus, the growing prevalence of epilepsy is contributing to the expansion of the antiepileptic drug market.
Leading companies in the antiepileptic drugs market are focusing on developing advanced formulations, such as intravenous (IV) antiepileptic drugs, to provide more effective treatment options for acute seizures and emergency situations. IV antiepileptic drugs are fast-acting medications administered directly into the bloodstream via injection or infusion, offering rapid seizure control, especially in emergencies or when oral medications are not suitable or effective. For instance, in January 2024, Eisai Co., Ltd., a Japan-based pharmaceutical firm, received manufacturing and marketing approval for Fycompa in Japan. Fycompa is a first-in-class, highly selective, non-competitive AMPA receptor antagonist that decreases neuronal hyper-excitation linked to seizures by targeting glutamate activity at AMPA receptors. The intravenous formulation was developed as an alternative for epilepsy patients who temporarily cannot take oral medication, such as during surgery, to reduce seizure risks associated with interrupted oral dosing. Fycompa is approved in over 75 countries and is used as an adjunctive treatment for partial-onset seizures and primary generalized tonic-clonic seizures in patients aged 4 years and older in Japan.
In August 2024, AbbVie, a U.S.-based biopharmaceutical company, acquired Cerevel Therapeutics for around $8.7 billion. This acquisition is intended to strengthen AbbVie’s neuroscience pipeline and enhance its capacity to develop treatments for neurological and psychiatric disorders. Cerevel Therapeutics is a U.S.-based biotechnology company specializing in the manufacture of antiepileptic drugs.
Major players in the antiepileptic drugs market are Pfizer Inc., Sanofi S.A., Novartis AG, Teva Pharmaceutical Industries Ltd., UCB S.A., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Jazz Pharmaceuticals plc, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Ltd., Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Supernus Pharmaceuticals Inc., SK Biopharmaceuticals Co. Ltd., Immedica Pharma AB, Neurelis Inc.
North America was the largest region in the antiepileptic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in antiepileptic drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the antiepileptic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Antiepileptic drugs (AEDs) are medications used to control or prevent seizures in people with epilepsy and other neurological disorders. They work by altering neurotransmitter levels or ion channel function in the brain. By stabilizing electrical activity in the brain, AEDs help decrease both the frequency and severity of seizures.
The main categories of antiepileptic drugs include first-generation, second-generation, and third-generation AEDs. First-generation AEDs were the earliest seizure treatments and act by stabilizing brain activity, though they often come with more side effects and complex pharmacokinetics. These drugs come in various forms, including dry and liquid formulations, and can be administered through multiple routes such as oral and intravenous. They are distributed through a range of channels, including hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.
The antiepileptic drugs market research report is one of a series of new reports that provides antiepileptic drugs market statistics, including the antiepileptic drugs industry global market size, regional shares, competitors with the antiepileptic drugs market share, detailed antiepileptic drugs market segments, market trends, opportunities, and any further data you may need to thrive in the antiepileptic drugs industry. This antiepileptic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The antiepileptic drugs market consists of sales of sodium channel blockers, calcium channel blockers, glutamate inhibitors, and gamma-aminobutyric acid (GABA) enhancers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Antiepileptic Drugs Market Characteristics3. Antiepileptic Drugs Market Trends And Strategies4. Antiepileptic Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Antiepileptic Drugs Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Antiepileptic Drugs Market34. Recent Developments In The Antiepileptic Drugs Market
5. Global Antiepileptic Drugs Growth Analysis And Strategic Analysis Framework
6. Antiepileptic Drugs Market Segmentation
7. Antiepileptic Drugs Market Regional And Country Analysis
8. Asia-Pacific Antiepileptic Drugs Market
9. China Antiepileptic Drugs Market
10. India Antiepileptic Drugs Market
11. Japan Antiepileptic Drugs Market
12. Australia Antiepileptic Drugs Market
13. Indonesia Antiepileptic Drugs Market
14. South Korea Antiepileptic Drugs Market
15. Western Europe Antiepileptic Drugs Market
16. UK Antiepileptic Drugs Market
17. Germany Antiepileptic Drugs Market
18. France Antiepileptic Drugs Market
19. Italy Antiepileptic Drugs Market
20. Spain Antiepileptic Drugs Market
21. Eastern Europe Antiepileptic Drugs Market
22. Russia Antiepileptic Drugs Market
23. North America Antiepileptic Drugs Market
24. USA Antiepileptic Drugs Market
25. Canada Antiepileptic Drugs Market
26. South America Antiepileptic Drugs Market
27. Brazil Antiepileptic Drugs Market
28. Middle East Antiepileptic Drugs Market
29. Africa Antiepileptic Drugs Market
30. Antiepileptic Drugs Market Competitive Landscape And Company Profiles
31. Antiepileptic Drugs Market Other Major And Innovative Companies
35. Antiepileptic Drugs Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Antiepileptic Drugs Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on antiepileptic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for antiepileptic drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antiepileptic drugs market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug: First Generation; Second Generation; Third Generation2) By Form: Dry; Liquid
3) By Route Of Administration: Oral; Intravenous; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Drug Stores
Subsegments:
1) By First Generation: Phenobarbital; Phenytoin; Carbamazepine; Valproate; Primidone; Ethosuximide2) By Second Generation: Lamotrigine; Gabapentin; Topiramate; Levetiracetam; Oxcarbazepine; Tiagabine; Felbamate; Zonisamide
3) By Third Generation: Lacosamide; Eslicarbazepine Acetate; Perampanel; Brivaracetam; Cenobamate
Key Companies Profiled: Pfizer Inc.; Sanofi S.A.; Novartis AG; Teva Pharmaceutical Industries Ltd.; UCB S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Sanofi S.A.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- UCB S.A.
- Eisai Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Jazz Pharmaceuticals plc
- Aurobindo Pharma Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Cipla Ltd.
- Amneal Pharmaceuticals Inc.
- Lupin Limited
- Zydus Lifesciences Ltd.
- Alkem Laboratories Ltd.
- Torrent Pharmaceuticals Ltd.
- Supernus Pharmaceuticals Inc.
- SK Biopharmaceuticals Co. Ltd.
- Immedica Pharma AB
- Neurelis Inc.